8 completed. 8 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow COVID 19: new trials by email Literature Review of COVID 19 trials Research Report on COVID 19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Colostrum From MERS-CoV Seropositive Camels for SARS-CoV-2 Infection - a Placebo-controlled Randomized Trial. Colostrum Nasal Spray, Water for injection - COVID 19 | Phase 1 / Phase 2 | Completed | Hadassah Medical Organization | 43 | 2023-05-01 | 2025-03-04 |
| Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 1: ILT101, 2: Placebo Comparator - COVID 19 | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2020-10-23 | 2021-10-04 |
| IMU-838 and Oseltamivir in the Treatment of COVID-19 IMU-838, Oseltamivir - Covid 19 | Phase 2 | Completed | University Hospitals Coventry and Warwickshire NHS Trust | 38 | 2020-06-15 | 2023-08-22 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebo - COVID 19, SARS-CoV 2 | Phase 2 | Completed | Kristin Hudock | 1 | 2020-05-20 | 2024-12-09 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebos - COVID 19, SARS-CoV 2 | Phase 2 | Completed | The Cleveland Clinic | 40 | 2020-05-20 | 2021-05-13 |
| COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19 Colchicine, Ruxolitinib 5 MG, Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] - COVID 19 | Phase 2 | Completed | Lomonosov Moscow State University Medical Research and Educational Center | 70 | 2020-05-08 | 2022-11-25 |
| A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection Fluvoxamine, Placebo - COVID 19, Coronavirus | Phase 2 | Completed | Washington University School of Medicine | 152 | 2020-04-10 | 2021-07-09 |
| Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19 Collagen-polyvinylpyrrolidone, Pirfenidone 1200 mg - COVID 19 | Phase 2 / Phase 3 | Completed | Materno-Perinatal Hospital of the State of Mexico | 36 | 2020-02-01 | 2024-09-05 |
COVID-19 (8) · Pneumonia (2) · Coronavirus Infections (1) · Respiratory Distress Syndrome (1)
Coronaviridae Infections (8) · Infections (8) · Lung Diseases (8) · Nidovirales Infections (8) · Pneumonia, Viral (8) · RNA Virus Infections (8) · Respiratory Tract Diseases (8) · Respiratory Tract Infections (8) · Virus Diseases (8) · Coronavirus Infections (7) · Pneumonia (6) · Respiration Disorders (1)
mavrilimumab (2) · Colchicine (1) · Fluvoxamine (1) · Injections (1) · Oseltamivir (1) · Standard of Care (1) · Water (1) · collagen-PVP (1) · pirfenidone (1) · ruxolitinib (1) · secukinumab (1)
Assistance Publique - Hôpitaux de Paris (1) · Hadassah Medical Organization (1) · Kristin Hudock (1) · Lomonosov Moscow State University Medical Research and Educational Center (1) · Materno-Perinatal Hospital of the State of Mexico (1) · The Cleveland Clinic (1) · University Hospitals Coventry and Warwickshire NHS Trust (1) · Washington University School of Medicine (1)
United States (3) · France (1) · Israel (1) · Mexico (1) · Russia (1) · United Kingdom (1)
Eric J Lenze, MD (1) · Kristin Hudock, MD (1) · Paul C Cremer, M. D. (1)
PMID 33754144, PMID 33180097, PMID 33240091, PMID 34658014, PMID 36396307, PMID 40329764